Novo Nordisk Rides a Sector Tailwind as CagriSema Data and Lilly's Shadow Set Up a November Reckoning
Published on 10/30/2026 at 16:51 | Editorial boerse-global.de
Shares in Novo Nordisk advanced 2.8% on Tuesday, lifted by the broader optimism coursing through the obesity-medicine space after Eli Lilly raised its revenue guidance. The Danish drugmaker's gain came a day after its own stock added 2.2% — a move that cannot be pinned to any single clinical announcement.
The twin catalysts behind the sector's mood are distinct, and investors would do well to keep them apart. Lilly, citing robust demand for its obesity and diabetes treatments, lifted its 2026 revenue forecast to $91bn–$92bn, according to Reuters. That is a vote of confidence in the market itself — but it comes from Novo Nordisk's most direct rival, and a swelling market can coexist with intensifying competition.
A Clinical Anchor, With Caveats
Novo Nordisk's own scientific case rests on data it presented on 20 October at the annual meeting of the Menopause Society. The company unveiled two post-hoc analyses of the REDEFINE 1 trial, one of which covered 2,309 women and examined weight loss achieved with CagriSema.
Under the company's assumptions — namely that treatment was adhered to as prescribed — average weight loss reached 25.0% after 68 weeks, against 3.0% for placebo. Two limitations frame how much weight that figure can bear: the analysis was retrospective, and it focused on women. The adherence assumption is itself part of the result, so reading the headline number alone omits a meaningful piece of the story.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The takeaway for shareholders is narrower than a verdict on the company's competitive standing. A post-hoc look answers a tightly defined question; it should not be inflated into a judgment on Novo Nordisk's future market position. What matters next is whether further results build a coherent picture — not whether the headlines keep coming.
Lilly's Retatrutide Raises the Bar
Competitive pressure supplies the counterweight. Eli Lilly reported that retatrutide, in the Phase III TRANSCEND-T2D-2 trial, delivered stronger improvements in blood sugar and weight than Ozempic after 80 weeks — a finding that ratchets up the strain on Novo Nordisk's GLP-1 franchise.
That comparison concerns Ozempic, not CagriSema, so it does not undercut the positive CagriSema findings. By the same token, those findings say nothing about how CagriSema stacks up against retatrutide. Collapsing results from different compounds into a single competitive verdict would be a risky move for investors.
The legal front adds another layer. A US judge on Monday declined Novo Nordisk's request for an injunction against advertising for Lilly's weight-loss medicines, Reuters reported. The ruling explicitly left open whether the advertisements were false or misleading, so it is no final judgment on their content.
Two Dates That Will Define the Story
Novo Nordisk will publish third-quarter and nine-month 2026 results on 4 November, before the Copenhagen market opens. That print is where the separation between sector-wide growth and the company's own trajectory becomes visible — evidence of how Novo Nordisk is holding up in a market defined by fierce demand.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Before that, the ObesityWeek congress in Washington from 14 to 17 November will feature 26 presentations of new data on the obesity portfolio. What is confirmed is the planned disclosure, not its significance for the stock. If the additional findings convincingly extend the existing evidence, a more favourable view of the clinical outlook is plausible; if they fall short of expectations, competitive pressure is likely to weigh more heavily. The value lies in the incremental insight, not the tally of abstracts.
Meanwhile, Novo Nordisk is pressing on with its share buyback programme. On Monday the company reported purchases of 1,200,000 B-shares during the period from 19 to 23 October — a standalone capital-return measure that should not be conflated with the demand signal emanating from Lilly's guidance.
For now, the stronger industry backdrop is propping up sentiment. Novo Nordisk's own numbers still have to earn it.
Ad
Novo Nordisk Stock: New Analysis - 30 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
